These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1675466)

  • 1. [Medical treatment of portal hypertension].
    Lebrec D
    Presse Med; 1991 Apr; 20(16):750-5. PubMed ID: 1675466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-blockers and portal hypertension, hemodynamic effects and prevention of recurrent gastrointestinal bleeding.
    Lebrec D
    Hepatogastroenterology; 1990 Dec; 37(6):556-60. PubMed ID: 1981204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-blockers in the prevention of gastrointestinal bleeding.
    Lebrec L
    Rev Invest Clin; 1990 Jul; 42 Suppl():159-64. PubMed ID: 19256157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of beta-blockers in the preventive treatment of rupture of esophageal varices].
    Calès P
    Acta Gastroenterol Belg; 1990; 53(4):409-17. PubMed ID: 1982912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of propranolol on portal hypertension].
    Kovacević N; Tomić D; Perisić-Savić M; Grbić R
    Srp Arh Celok Lek; 1992 Jun; 120 Suppl 4():62-4. PubMed ID: 18193814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding.
    Lebrec D
    Pharmacol Ther; 1994; 61(1-2):65-107. PubMed ID: 7938175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of upper gastrointestinal bleeding from portal hypertension in cirrhosis: rationale for medical treatment.
    Pagliaro L; D'Amico G; Tinè F; Pasta L
    Dig Dis; 1992; 10 Suppl 1():56-64. PubMed ID: 1362378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis.
    Alvarado-Tapias E; Ardevol A; Garcia-Guix M; Montañés R; Pavel O; Cuyas B; Graupera I; Brujats A; Vilades D; Colomo A; Poca M; Torras X; Guarner C; Concepción M; Aracil C; Torres F; Villanueva C
    J Hepatol; 2020 Oct; 73(4):829-841. PubMed ID: 32298768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-blockers in portal hypertension: new developments and controversies.
    Tripathi D; Hayes PC
    Liver Int; 2014 May; 34(5):655-67. PubMed ID: 24134058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-blockers for prophylaxis of bleeding from esophageal varices in cirrhotic portal hypertension. Review of the literature.
    Zoller WG; Gross M
    Eur J Med Res; 1996 Jun; 1(9):407-16. PubMed ID: 9353240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term pharmacologic therapy of portal hypertension.
    Burroughs AK; McCormick PA
    Surg Clin North Am; 1990 Apr; 70(2):319-39. PubMed ID: 1969683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
    Villanueva C; Aracil C; Colomo A; Hernández-Gea V; López-Balaguer JM; Alvarez-Urturi C; Torras X; Balanzó J; Guarner C
    Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Portal hypertension: beta-receptor blockers for the prevention of upper intestinal bleeding].
    Sauerbruch T
    Dtsch Med Wochenschr; 1992 Mar; 117(13):520-1. PubMed ID: 1348025
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term management of variceal bleeding: the place of pharmacotherapy.
    Lebrec D
    World J Surg; 1994; 18(2):229-32. PubMed ID: 7913784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review: pharmacotherapeutic agents in the treatment of portal hypertension.
    Lebrec D
    J Gastroenterol Hepatol; 1997 Feb; 12(2):159-66. PubMed ID: 9083918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological methods for the prevention of first and recurrent bleeding from esophagogastric varices.
    Fleig WE
    Z Gastroenterol; 1988 Sep; 26 Suppl 2():40-8. PubMed ID: 2903596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cirrhotic portal hypertension: current and future medical therapy for primary and secondary prevention of variceal bleeding.
    Laleman W; Nevens F
    Minerva Med; 2006 Aug; 97(4):325-45. PubMed ID: 17008837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperkinetic circulatory syndrome in patients with presinusoidal portal hypertension. Effect of propranolol.
    Braillon A; Moreau R; Hadengue A; Roulot D; Sayegh R; Lebrec D
    J Hepatol; 1989 Nov; 9(3):312-8. PubMed ID: 2607120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window.
    La Mura V; Tosetti G; Primignani M; Salerno F
    World J Gastroenterol; 2015 Feb; 21(8):2265-8. PubMed ID: 25741132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study.
    Hobolth L; Bendtsen F; Hansen EF; Møller S
    Dig Liver Dis; 2014 Mar; 46(3):251-6. PubMed ID: 24290869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.